Get the latest news alerts: at Twitter.

Wire reports

Two drug giants, each with a growing presence in the Research Triangle Park, reported strong revenue growth Tuesday before the markets opened.

(NYSE: PFE) sees its first-quarter profit and revenue skyrocket, thanks to its giant acquisition of Wyeth last October.

The maker of cholesterol fighter Lipitor and impotence pill Viagra says its adjusted income for the first three months totals $4.88 billion, or 60 cents per share. That’s up 33 percent from $3.67 billion or 54 cents a share, a year earlier.

With the addition of Wyeth blockbusters such as antidepressant Effexor and children’s vaccine Prevnar, Pfizer’s revenue hits $16.75 million. That’s up 54 percent from $10.87 billion a year earlier.

Analysts polled by Thomson Reuters, on average, were expecting slightly lower earnings per share of 53 cents and revenue of $16.58 billion.

Pfizer has a major presence in the Research Triangle Park, N.C. area with the former Wyeth production plant in Sanford, R&D operations in RTP and its poultry health group built around Embrex, the RTP firm in acquired in 2006.

Merck’s quarter

Meanwhile, (NYSE: MRK) says double-digit sales growth for a half-dozen of its top medicines fueled a 7 percent jump in first-quarter sales. But charges for its November deal to buy Schering-Plough Corp. pulled profit down sharply.

Merck is the process of expanding its production facility in Durham, N.C.

The maker of asthma and allergy pill Singulair and cholesterol drugs Vytorin and Zetia is reporting earnings of $298.8 million, or just 9 cents per share.

A year earlier, before Merck’s megadeal to buy Schering-Plough for $41 billion, Merck earned 67 cents per share on revenue of $5.39 billion. The new Schering products helped boost sales to $11.42 billion.

Excluding 74 cents worth of charges, Merck would have earned 83 cents a share. Analysts surveyed by Thomson Reuters expected, on average, earnings per share of 75 cents and revenue of $11.18 billion.